Patients with high pulmonary CXCR4 signals on follow-up PET scans after 6 weeks into treatment have a statistically worse outcome at 12 months [314], predicting IPF patient outcomes with pirfenidone. This evidence concerns the gene CXCR4 and idiopathic interstitial pneumonia.